Skip to main content

Table 1 Demographic and clinical characteristics of the study population (n = 515)

From: A prospective study of hepatic safety of statins used in very elderly patients

Variables

Percent (N)

Age (years)

83.8 ± 3.4

 80 ≃ 85

63.5% (327)

 85 ≃ 90

29.5% (152)

  ≥ 90

7% (36)

Sex

 Male

79.6% (410)

 Female

20.4% (105)

Hepatitis B

 Yes

4.3% (22)

 No

95.7% (493)

Fatty liver

 Yes

9.1% (47)

 No

90.9% (468)

Biliary calculus

 

 Yes

17.1% (88)

 No

82.9% (427)

Other diseasesa

  ≤ 2

6% (31)

 3 ≃ 5

41.2% (212)

  ≥ 5

52.8% (272)

Other drugsb

  < 5

19.2% (99)

 5 ≃ 10

71.5% (368)

  ≥ 10

9.3% (48)

Drinking habitsc

 No drinking

95.3% (491)

 Mild to moderate

2.7% (14)

 Heavy

1.9% (10)

Statin variety

 Simvastatin

19.1% (98)

 Fluvastatin

22.5% (116)

 Pravastatin

15.5% (80)

 Rosuvastatin

16.5% (85)

 Atorvastatin

26.4% (136)

Statin dose

 Low

13.6% (70)

 Standard

86.4% (445)

  1. aIncluding hypertension, diabetes, cerebral infarction, atrial fibrillation, chronic bronchitis, chronic obstructive pulmonary disease, chronic gastritis, osteoporosis, benign prostatic hyperplasia, and biliary calculus
  2. bIncluding antihypertensive agents, antidiabetic agents, clopidogrel, aspirin, beta-blockers, isosorbide mononitrate, trimetazidine, citicoline, cilostazol, warfarin, digoxin, ambroxol, aminophylline, rebamipide, rabeprazole, calcitriol, calcium carbonate, oral bisphosphonates, finasteride, tamsulosin, and digestive enzymes
  3. cNo drinking: not drinking in a previous year; light drinkers: current use of 3 drinks per week; moderate drinkers: current use of 3 to 7 drinks per week for women, and 3 to 14 drinks per week for men; heavy drinkers: current use of more than 7 drinks per week for women and 14 drinks per week for men
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us